Correlation between methylation levels of CpG sites in the RUNDC3B, ENSG00000167210, SPON2, and LRP1B genes and clinical outcome of ALL patients. Probability of relapse (p-relapse) in patients stratified into 3 groups according to beta values less than 0.25, 0.25 to 0.75, and greater than 0.75 for methylation of (A) the CpG site in the ENSG00000167210 gene (chr18, position 42 434,938) in patients with BCP ALL; (B) the CpG site in the RUNDC3B gene (chr7, position 87 096,309) in patients with BCP ALL; (C) the CpG site in the SPON2 gene (chr4, position 1,155,890) in patients with BCP ALL; and (D) CpG site in the LRP1B gene (chr2, position 142,605,854) in patients with T-ALL. The p-relapse is given on the y-axis and the observation time in months on the x-axis. The P values calculated by the Gray test are given in the panels.